Accuracy of Canine Scent Detection of Non-Small Cell Lung Cancer in Blood Serum.

Conclusion: Trained dogs were able to identify non-small cell lung cancer samples from healthy controls. The findings of this study provide a starting point for a larger-scale research project designed to explore the use of canine scent detection as a tool for cancer biomarkers. PMID: 31206136 [PubMed - as supplied by publisher]
Source: Journal of the American Osteopathic Association - Category: Complementary Medicine Tags: J Am Osteopath Assoc Source Type: research

Related Links:

Dr Tony Mok of Hong Kong University reviews key studies on non-small cell lung cancer therapies, presented at the 2019 annual meeting of the European Society for Medical Oncology (ESMO).Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None ReCAP Source Type: news
A liquid biopsy may be able to predict the efficacy of EGFR-targeted tyrosine kinase inhibitors in patients with non –small cell lung cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
les Ricordel Non-small cell lung cancer (NSCLC) has been the leading cause of cancer-related death worldwide, over the last few decades. Survival remains extremely poor in the metastatic setting and, consequently, innovative therapeutic strategies are urgently needed. Inhibitor of Growth Gene 2 (ING2) is a core component of the mSin3A/Histone deacetylases complex (HDAC), which controls the chromatin acetylation status and modulates gene transcription. This gene has been characterized as a tumor suppressor gene and its status in cancer has been scarcely explored. In this review, we focused on ING2 and other mSin3A/HDAC ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Lung cancer is one of the leading causes of death worldwide [1]. Approximately 80% of lung cancer patients are consistent with non-small cell histology (NSCLC) [2]. The Tumor-Node-Metastasis (TNM) system is used to classify and stratify patients by prognosis according to tumor size (T), lymph node (LN) involvement (N) and presence of distant metastases (M). Its actual valid 8th edition was implemented in 2016 using clinical information from 70,976 consecutive NSCLC patients treated between 1999 and 2010 in 16 countries [3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractBackgroundIt is known that there are insufficient prognostic factors for non-small cell lung cancer (NSCLC). It was reported that PD-L1 was a prognostic factor for NSCLC,and c-Myc regulated the expression of PD-L1. Herein, we investigated c-Myc and PD-L1 expression and their association with overall survival (OS) in NSCLC.MethodsFormalin-fixed paraffin-embedded specimens were obtained from 128 patients with surgically resected primary NSCLC. Immunohistochemistry was used to assess the expression of PD-L1 and c-Myc in this study. Pearson ’s Chi squared test or Fisher’s exact test was used to analyze the ...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 19 October 2019Source: The Annals of Thoracic SurgeryAuthor(s): Melanie P. Subramanian, Graham A. Colditz
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
ConclusionsAt the current price of pemetrexed, the combination of pemetrexed plus cisplatin was not found to be a cost-effective first-line regimen for patients with non-small cell lung cancer at the local Thai threshold compared with the gemcitabine plus cisplatin and carboplatin plus paclitaxel regimens.
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research
Publication date: Available online 19 October 2019Source: Respiratory Medicine Case ReportsAuthor(s): V.R. Anjali, Rambha Pandey, Astha Srivastava, Madhu Rajeshwari, Durgatosh Pandey, M.C. SharmaAbstractWith the advent of targeted therapies there was a paradigm shift in the treatment of metastatic adenocarcinoma of lung. Immuno-histopathology and molecular subtyping in metastatic adenocarcinoma lung have enabled personalized treatment for each patient. Oncogenic driver mutations in non-small cell lung cancer are commonly EGFR (Epidermal Growth Factor Receptor) gene mutation and ALK (Anaplastic Lymphoma Kinase) gene rearran...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors have been developed for the treatment of EML4-ALK-rearranged non-small-cell lung cancer, with the newer generation agents brigatinib, alectinib and lorlatinib showing pronounced central nervous system activities. Intracranial efficacy is an important feature for these agents, as metastatic lesions frequently occur in the central nervous system in the ALK-positive setting. Here, we report on an updated case of a patient who received her diagnosis in 2005 and has had disease progression with new lesions on six occasions over the last 8 years. During the firs...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
More News: Cancer | Cancer & Oncology | Complementary Medicine | Lung Cancer | Non-Small Cell Lung Cancer | Study | Training | Universities & Medical Training